Double Dhamaka! 1:1 Bonus Share & Re 0.50/Share Dividend: Multibagger Pharma Stock with 285 Per Cent Returns in Just 2 Years
The company has a market cap of over Rs 1,200 crore and the stock has given multibagger returns of 285 per cent in just 2 years.
The Board of Remus Pharmaceuticals Limited has recommended a dividend of Re 0.50 per equity share (face value Rs 10) for the Financial Year 2024-25, pending shareholder approval at the upcoming Annual General Meeting (AGM). Additionally, the Board has approved a 1:1 bonus issue, meaning one new fully paid-up equity share of Rs 10 will be issued for every one existing fully paid-up equity share of Rs 10 held by eligible shareholders. The record date for the bonus issue will be announced later.
Incorporated in 2015, Remus Pharmaceuticals Limited operates in the trading and export of Active Pharmaceutical Ingredients (API) and Finished Formulations, alongside offering technical consultancy services. The company and its group specialise in marketing pharmaceutical products across critical care, neurology, cardiology and diabetic categories, with a recent focus on off-patent molecules and complex generics. Their business model involves getting finished pharmaceutical formulations manufactured through a loan license or contract manufacturing arrangements and their operations are divided into marketing and distribution of finished formulations globally, trading of API and providing technical consultancy for pharmaceutical dossier preparation.
DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, download the service details here.
The company demonstrated robust financial performance in FY25, showcasing significant growth both year-over-year and in the second half compared to the first half. Revenue from operations for H2 FY25 reached Rs 347.75 crore, marking a 27.56 per cent increase from H1FY25's Rs 272.61 crore. Similarly, Profit After Tax (PAT) grew by 15.25 per cent from Rs 17.85 crore in H1FY25 to Rs 20.57 crore in H2FY25. On a consolidated annual basis, FY25 revenue from operations surged to Rs 620.36 crore, a remarkable 191.33 per cent increase from FY24's Rs 212.94 crore. Concurrently, PAT for FY25 saw a substantial 58.23 per cent rise, reaching Rs 38.42 crore compared to Rs 24.28 crore in FY24.
The company has a market cap of over Rs 1,200 crore and the stock has given multibagger returns of 285 per cent in just 2 years. The shares of the company have a PE of 42x, an ROE of 17 per cent and an ROCE of 23.2 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.